BETHESDA, MD. July 25, 2019 - BrainScope announced today that it has successfully completed a nearly five year, $9.9 million U.S. Department of Defense research contract supporting the development and validation of an objective marker of the presence and severity of concussion. In a large blinded validation study, the system demonstrated its ability to help clinicians assess concussion at the..
BrainScope Advances its Commercial Adoption and Appoints Industry Veteran Susan Hertzberg as CEO
Founding CEO Michael Singer to Serve as Executive Chairman
BETHESDA, MD. June 24, 2019 - BrainScope announced today the appointment of Susan Hertzberg as Chief Executive Officer. This is the 4th equity-backed venture that Hertzberg will helm. She is a proven commercial stage leader with an..
Over 30% Reduction in Unnecessary Head CT Scans When Integrating FDA-Cleared BrainScope One
Use in the Emergency Room demonstrates BrainScope One can reduce patient radiation exposure, decrease use of hospital resources, and shorten throughput times
BETHESDA, MD. May 6, 2019 - BrainScope announced today the publication of a study conducted by physicians at Washington University Barnes Jewish..
BrainScope Completes Large-Scale Clinical Studies of Concussion in Universities, High Schools and Concussion Clinics
Culmination of Four-Year Project With U.S. Department of Defense and NFL-GE Research Funding
BETHESDA, MD. March 28, 2019– BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it had..
BrainScope Announces Publication Describing Proprietary Concussion Biomarker to Assess Potential Severity and Predict Prolonged Recovery
Future Capability Could Aid in Objective Return-to-Activity Decisions
BETHESDA, MD. January 15, 2019– BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that researchers have..
BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment
New Concussion-Specific FDA Labeling Adds to Existing BrainScope Claims Complements Multi-Modal Technology Platform and Extensive Intellectual Property Portfolio To Address New Brain and Behavioral Health Conditions
BETHESDA, MD. January 2, 2019– BrainScope®, a medical neuro-technology company focused on..
Ron Klain Joins BrainScope Board of Directors
Brings Extensive Experience in Industry, Government and Public Health
BETHESDA, MD. December 11, 2018– BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that Ron Klain, Executive Vice President and General Counsel of the investment firm Revolution, has joined..
BETHESDA, MD. November 13, 2018– BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it has fulfilled orders for over 170 BrainScope One handheld devices and over 7,500 individual patient headsets to U.S. Army bases across the world. U.S. Army medics and clinicians continue to receive the training necessary..
Artificial Intelligence and Multi-Modal Capabilitiesto Optimize Personalized Concussion Assessment
BETHESDA, MD. September 4, 2018– BrainScope today announced that it has been awarded a research contract by the United States Department of Defense (DOD) valued at $4.5 million to create and integrate ocular capabilities into its handheld, multi-parameter mild Traumatic Brain Injury (mTBI) and..
August 02, 2018 06:00 AM Eastern Daylight Time
BETHESDA, MD.--(BUSINESS WIRE)--BrainScope today announced its second consecutive nomination for the 2018 Annual Prix Galien USA Awards for "Best Medical Technology"? product. Its flagship BrainScope One product is a multi-modal, comprehensive, handheld capability to help clinicians objectively and rapidly assess and triage head injured patients..